Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 19, Issue 6, Pages 267-272
http://dx.doi.org/10.1155/2004/834309

Clinical Interest of the Combined Use of Serum CD26 and Alpha-L-Fucosidase in the Early Diagnosis of Colorectal Cancer

Daniel Ayude,1 María Páez de la Cadena,1 Oscar Javier Cordero,2 Montserrat Nogueira,2 José Ayude,3 Almudena Fernández-Briera,1 and Francisco Javier Rodríguez-Berrocal1

1Department of Biochemistry, Genetics, and Immunology, University of Vigo, 36200 Vigo, Spain
2Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain
3Department of Computer Sciences, University of Vigo, 36200 Vigo, Spain

Received 13 July 2004; Accepted 13 July 2004

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The purpose of this study was to assess if the combination of CD26 and alpha-L-fucosidase has a role in the diagnosis of colorectal cancer, paying particular attention to the stages in which the tumour is not yet disseminated. CD26 concentration and alpha-L-fucosidase activity were determined in sera from 110 colorectal cancer patients and 46 donors. The combination of CD26 and alpha-L-fucosidase showed a specificity of 100% with a sensitivity of 64% in the diagnosis of colorectal cancer. Interestingly, the combination of both markers had a sensitivity of 75% in the stage I at the highest specificity (100%), providing also high sensitivity levels for the other non-disseminated stages (66% for stages II and III). In conclusion, the combined use of CD26 and alpha-L-fucosidase offers high sensitivity with high specificity in the diagnosis of colorectal cancer, especially at the earliest stage (TNM I).